GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

NICE backs Keytruda for incurable cervical cancer via CDF

Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe

Merck suffers a setback in its TIGIT programme

Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.

Merck drops last phase 3 Keytruda trial in prostate cancer

KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &

Supercharge Targeting FcRn & FcγR Pathways via Fc Optimi...